SAGE250117P22500
- 5.10
- 0.000.00%
Sage Therapeutics Newsroom
TD Cowen Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $9
Piper Sandler Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Maintains Target Price $9
Scotiabank Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Maintains Target Price $14
Scotiabank Remains a Buy on SAGE Therapeutics (SAGE)
Piper Sandler Sticks to Its Buy Rating for SAGE Therapeutics (SAGE)
Jefferies Initiates Sage Therapeutics(SAGE.US) With Hold Rating, Announces Target Price $8
Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Truist Financial Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and SAGE Therapeutics (SAGE)
Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Morgan Stanley Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $9
Hold Rating for SAGE Therapeutics Amid Biogen Acquisition Offer and Pipeline Challenges
RBC Raises Price Target on SAGE Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk
Sage Therapeutics Is Maintained at Overweight by Piper Sandler
Piper Sandler Initiates Sage Therapeutics(SAGE.US) With Buy Rating, Announces Target Price $9
Stifel Maintains Hold on Sage Therapeutics, Lowers Price Target to $6
Sage Therapeutics Analyst Ratings
Stifel Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Cuts Target Price to $6
Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Announces Target Price $10
Mizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)